Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 4Phase 1 4Phase EARLY_PHASE1 1

Status

Withdrawn 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Gynecologic 1

Conditions

Pancreatic Neoplasms 2Phase IB 1Mesothelioma, Malignant 1Carcinoma, Endometrioid 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × OTHER × defactinib × Clear all
NCT03875820 2026-03-10

FRAME

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
87 enrolled
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Endometrioid

NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

NCT02546531 2021-07-20

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Washington University School of Medicine

Phase 1 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04201145 2020-11-17

Pembrolizumab + Defactinib In Pleural Mesothelioma

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡